American International Group Inc. Takes $229,000 Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

American International Group Inc. purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 11,235 shares of the company’s stock, valued at approximately $229,000.

Several other large investors have also modified their holdings of ELVN. Barclays PLC bought a new stake in shares of Enliven Therapeutics in the 1st quarter valued at about $158,000. Bank of New York Mellon Corp bought a new stake in shares of Enliven Therapeutics in the 1st quarter valued at about $335,000. Tower Research Capital LLC TRC bought a new stake in shares of Enliven Therapeutics in the 1st quarter valued at about $36,000. Citigroup Inc. bought a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $247,000. Finally, FMR LLC bought a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $69,280,000. Institutional investors own 95.08% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder 5Am Partners Vi, Llc sold 440,000 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $16.00, for a total transaction of $7,040,000.00. Following the completion of the transaction, the insider now owns 887,507 shares in the company, valued at approximately $14,200,112. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, major shareholder 5Am Partners Vi, Llc sold 440,000 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $16.00, for a total transaction of $7,040,000.00. Following the completion of the transaction, the insider now owns 887,507 shares in the company, valued at approximately $14,200,112. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Samuel Kintz sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $13.81, for a total transaction of $165,720.00. The disclosure for this sale can be found here. Insiders sold a total of 678,072 shares of company stock worth $10,548,422 in the last 90 days. 45.80% of the stock is owned by corporate insiders.

Enliven Therapeutics Stock Up 1.3 %

NASDAQ ELVN opened at $10.54 on Tuesday. The firm has a market cap of $434.37 million, a PE ratio of 3.29 and a beta of 1.13. The company has a 50 day moving average price of $12.97 and a 200 day moving average price of $16.73. Enliven Therapeutics, Inc. has a 52 week low of $9.98 and a 52 week high of $25.34.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene.